Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Fennec Pharmaceuticals Q1 2026 Earnings
Business earnings report

Fennec Pharmaceuticals Q1 2026 Earnings

Analysis based on 6 articles · First reported May 14, 2026 · Last updated May 14, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The strong Q1 2026 financial results of Fennec Pharmaceuticals, with a 73% increase in net revenues and positive cash flow, are likely to be viewed favorably by the market, potentially leading to increased investor confidence and a positive impact on the company's stock price. The continued growth of PEDMARK adoption and new clinical studies further reinforce the company's market position and future revenue potential.

Pharmaceuticals Biotechnology
Event Summary

Fennec Pharmaceuticals reported its financial results for the first quarter ended March 31, 2026, showcasing significant growth with total net revenues of $15.1 million, a 73% increase year-over-year. The company highlighted the expanding adoption of its product PEDMARK, which is indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients. Fennec Pharmaceuticals also announced the initiation of a third institution-led clinical study by the University of Arizona Cancer Center to evaluate PEDMARK in adolescent and young adult and adult patients with head and neck and testicular cancers. Additionally, four abstracts evaluating PEDMARK were accepted for the upcoming 2026 American Society of Clinical Oncology Annual Meeting. The company's cash and cash equivalents increased to $40.1 million, and management anticipates sufficient funding for its current operating plan. Fennec Pharmaceuticals' CEO, Jeff Hackman, expressed confidence in the company's momentum and sustained growth throughout 2026.

Key Actions
80 Fennec Pharmaceuticals announced financial results release
60 Fennec Pharmaceuticals expanded sales organization
50 Fennec Pharmaceuticals accepted abstracts American Society of Clinical Oncology
Entities Involved
stock
Fennec Pharmaceuticals
Fennec Pharmaceuticals reported strong Q1 2026 financial results with a 73% year-over-year increase in net revenues, driven by the growing adoption of its product PEDMARK. The company also initiated a new clinical study for PEDMARK and will present abstracts at the ASCO Annual Meeting, indicating positive business momentum and potential for sustained growth.
Importance 100 Sentiment 70
per
Jeff Hackman
Jeff Hackman, CEO of Fennec Pharmaceuticals, expressed encouragement regarding the company's continued growth and the expanding clinical interest in PEDMARK, highlighting strategic enhancements to the sales force and the positive impact of the Fennec HEARS program.
Importance 50 Sentiment 60
priv
Norgine
Norgine is the exclusive licensing partner for Fennec Pharmaceuticals' product PEDMARQSI in Europe, the UK, Australia, and New Zealand, contributing to the global commercialization of the drug.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration approved PEDMARK in September 2022, making it the first and only approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients.
Importance 10 Sentiment 0
govactor
International — European Commission
The International — European Commission approved PEDMARQSI in June 2023, further expanding the market reach for Fennec Pharmaceuticals' product.
Importance 10 Sentiment 0
cnt
United Kingdom
The United Kingdom approved PEDMARQSI in October 2023, contributing to the international commercialization of Fennec Pharmaceuticals' drug.
Importance 10 Sentiment 0
ngo
American Society of Clinical Oncology
Four abstracts evaluating PEDMARK were accepted as part of the 2026 American Society of Clinical Oncology Annual Meeting program, showcasing further research and recognition of the product.
Importance 10 Sentiment 0
cnt
Australia
Australia is one of the regions where Norgine commercializes PEDMARQSI under a licensing agreement with Fennec Pharmaceuticals.
Importance 5 Sentiment 0
cnt
New Zealand
New Zealand is one of the regions where Norgine commercializes PEDMARQSI under a licensing agreement with Fennec Pharmaceuticals.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.